Drug transport in HEMA conjunctival inserts containing precipitated drug particles

Journal of Colloid and Interface Science

Volumn 347, Issue 1, 2010, Pages 31-42

  Gupta, Chhavi ^a   Chauhan, Anuj ^a  

^a University of Florida   (United States)

Author keywords

Conjunctival inserts; Cyclosporine; Diffusion; Dry eyes; HEMA; Mass transfer resistance; Model; Ophthalmic drug delivery; Particle dispersion in gels

Indexed keywords

DRY EYE; HEMA; MASS TRANSFER RESISTANCE; MASS TRANSFER RESISTANCES; OPHTHALMIC DRUG DELIVERY; PARTICLE DISPERSION;

BOUNDARY LAYERS; DIFFUSION; DISPERSIONS; GELS; LOADING; MATHEMATICAL MODELS; SCANNING ELECTRON MICROSCOPY;

CONTROLLED DRUG DELIVERY;

2 HYDROXYETHYL METHACRYLATE; CYCLOSPORIN A; CYCLOSPORIN; DRUG CARRIER; METHACRYLIC ACID DERIVATIVE;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSS LINKING; DIFFUSION; DISPERSION; DRUG BIOAVAILABILITY; DRUG TRANSPORT; MATHEMATICAL MODEL; POLYMERIZATION; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; THERMODYNAMICS; CHEMISTRY; CONJUNCTIVA; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG STABILITY; DRY EYE SYNDROMES; METABOLISM; PRECIPITATION; RADIATION SCATTERING; THEORETICAL MODEL;

CHEMICAL PRECIPITATION; CONJUNCTIVA; CYCLOSPORINE; DIFFUSION; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; DRY EYE SYNDROMES; METHACRYLATES; MICROSCOPY, ELECTRON, SCANNING; MODELS, THEORETICAL; SCATTERING, RADIATION;

EID: 77952891938     PISSN: 00219797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcis.2010.03.037     Document Type: Article

References (37)

1. Nichols J.J., Ziegler C., Mitchell G.L., Nichols K.K. Self-reported dry eye disease across refractive modalities. Invest Ophthalmol. Visual Sci. 2005, 46:1911-1914.
2. Doughty M.J., Fonn D., Richter D., Simpson T., Caffery B., Gordon K. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. Optom. Vision Sci. 1997, 74:624-631.
3. McMonnies C.W., Ho A. Marginal dry eye diagnosis: history versus biomicroscopy. The Preocular Tear Film in Health, Disease, and Contact Lens Wear 1986, 32-40. Dry Eye Institute, Lubbuck, TX. F.J. Holly (Ed.).
4. Begley C.G., Chalmers R.L., Mitchell G.L., et al. Characterization of ocular surface symptoms from optometric practices in North America. Cornea 2001, 20:610-618.
5. Guillon M., Cooper P., Maissa C., Girard-Claudon K. Dry eye symptomatology of contact lens wearers and nonwearers. Adv. Exp. Med. Biol. 2002, 506:945-949.
6. Liu Zuguo, Pflugfelder Stephen C. Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency. Ophthalmology 1999, 106:939-943.
7. Zhu Heng, Chauhan Anuj A mathematical model for tear drainage through the canaliculi. Curr. Eye Res. 2005, 30:621-630.
8. Zhu Heng, Chauhan Anuj Effect of viscosity on tear drainage and ocular residence time. Optom. Vision Sci. 2008, 85:715-725.
9. Beetham W.P. Filamentary keratitis. Trans. Am. Ophthalmol. Soc. 1935, 33:413-435.
10. Hamano T. Lacrimal duel occlusion for the treatment of dry eye. Sem. Ophthalmol. 2005, 20:71-74.
11. Goto E., Yagi Y., Kaido M., et al. Improved functional visual acuity after punctal occlusion in dry eye patients. Am. J. Ophthalmol. 2003, 135:704-705.
12. Coukell A.J., Plosker G.L. Cyclosporin microemulsion (Neoral (R))-A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation. Pharmacoeconomics 1998, 14:691-708.
13. Kivisto K.T. A review of assay-methods for cyclosporine - clinical implications. Clin. Pharmacokinet. 1992, 23:173-190.
14. Read R.A. Treatment of canine nictitans plasmacytic conjunctivitis with 0.2 percent cyclosporine ointment. J. Small Anim. Pract. 1995, 36:50-56.
15. Neumann W., SchulteNeumann A.L. Use of cyclosporin A (Optimmune eye-ointment) in dogs. Prakt. Tierarzt 1997, 78:954.
16. http://www.allergan.com.
17. Di Colo G., Burgalassi S., Chetoni P., Fiaschi M.P., Zambito Y., Saettone M.F. Gel-forming erodible inserts for ocular controlled delivery of ofloxacin. Int. J. Pharm. 2001, 215:101-111.
18. Di Colo G., Zambito Y., Burgalassi S., Serafini A., Saettone M.F. Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts based on poly(ethylene oxide). Int. J. Pharm. 2002, 248:115-122.
19. Chetoni Patrizia, Colo Giacomo Di, Grandi Massimo, Morelli Marco, Fabrizio Saettone M., Darougar Sohrab Silicone rubber/hydrogel composite ophthalmic inserts: preparation and preliminary in vitro/in vivo evaluation. Eur. J. Pharm. Biopharm. 1998, 46:125-132.
20. Hitoshi Sasaki, Choyu Tei, Koyo Nishida, Junzo Nakamura Drug release from an ophthalmic insert of a beta-blocker as an ocular drug delivery system. J. Control. Release 1993, 27:127-137.
21. Hill John C. Slow-release artificial tear inserts in the treatment of dry eyes in patients with rheumatoid arthritis. Brit. J. Ophthalmol. 1989, 73:151-154.
22. Punch P.I., Costa N.D., Edwards M.E., Wilcox G.E. J. Vet. Pharmacol. Ther. 1987, 10:37-42.
23. Lacrisert [package insert], Aton Pharma Inc., Lawrenceville, NJ, 2007.
24. Katz I.M., Blackman W.M. A soluble sustained-release ophthalmic delivery unit. Am. J. Ophthalmol. 1977, 83:728-734.
25. Lamberts D.W., Pavan-Langston D., Chu W. A clinical study of slow-releasing artificial tears. Ophthalmology 1978, 85:794-800.
26. Urtti A., Pipkin J.D., Rork G., Repta A.J. Controlled drug delivery devices for experimental ocular studies with timolol. 1. In vitro release studies. Int. J. Pharm. 1990, 61:235-240.
27. Brinkman H.C. A calculation of the viscous force exerted by a flowing fluid on a dense swarm of particles. Appl. Sci. Res. A 1947, 27-34.
28. Phillips R.J., Deen W.M., Brady J.F. Hindered transport of spherical macromolecules in fibrous membranes and gels. AICHE J. 1989, 35:1761-1769.
29. Solomentsev Y.E., Anderson J.L. Rotation of a sphere in Brinkman fluids. Phys. Fluids 1996, 8:1119-1121.
30. Monticelli M.V., Chauhan A., Radke C.J. The effect of water hydraulic permeability on the settling of a soft contact lens on the eye. Curr. Eye Res. 2005, 30:329-336.
31. Prausnitz Mark R., Noonan Jeremy S. Permeability of Cornea, Sclera, and conjuncitva: a literature analysis for drug delivery to the eye. J. Pharm. Sci. 1998, 87:1479-1488.
32. Kapoor Yash, Chauhan Anuj Drug and surfactant transport in cyclosporine A and Brij 98 laden p-HEMA hydrogels. J. Colloid Interface Sci. 2008, 322:624-633.
33. Ismailos G., Peppas C., Dressman J., Macheras P. Unusual solubility behavior of cyclosporine A in aqueous media. J. Pharm. Pharmacol. 1991, 43:287-289.
34. Schoenwald R.D. Ocular drug delivery, pharmacokinetic considerations. Clin. Pharmacokinet. 1990, 18:255-269.
35. Watsky M.A., Jablonski M.M., Edelhauser H.F. Comparison of conjunctival and corneal surface areas in rabbit and human. Curr. Eye Res. 1988, 7:483-486.
36. Zhu Heng, Chauhan Anuj A mathematical model for ocular and tear solute balance. Curr. Eye Res. 2005, 30:841-854.
37. Meadows D.L., Paugh J.R., Joshi A., Mardaunt J. A novel method to evaluate residence time in humans using non-penetrating fluorescent tracer. Invest. Ophthalmol. Vis. Sci. 2002, 43:1032-1039.